Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

PEPCK1 Antisense Oligonucleotide Prevents Adiposity and Impairs Hepatic Glycogen Synthesis in High-Fat Male Fed Rats.

Endocrinology | 2019

The increased hepatic gluconeogenesis in type 2 diabetes mellitus has often been ascribed to increased transcription of phosphoenolpyruvate carboxykinase 1, cystolic form (PEPCK1), although recent evidence has questioned this attribution. To assess the metabolic role of PEPCK1, we treated regular chow fed and high-fat fed (HFF) male Sprague-Dawley rats with a 2'-O-methoxyethyl chimeric antisense oligonucleotide (ASO) against PEPCK1 and compared them with control ASO-treated rats. PEPCK1 ASO effectively decreased PEPCK1 expression in the liver and white adipose tissue. In chow fed rats, PEPCK1 ASO did not alter adiposity, plasma glucose, or insulin. In contrast, PEPCK1 ASO decreased the white adipose tissue mass in HFF rats but without altering basal rates of lipolysis, de novo lipogenesis, or glyceroneogenesis in vivo. Despite the protection from adiposity, hepatic insulin sensitivity was impaired in HFF PEPCK1 ASO-treated rats. PEPCK1 ASO worsened hepatic steatosis, although without additional impairments in hepatic insulin signaling or activation of inflammatory signals in the liver. Instead, the development of hepatic insulin resistance and the decrease in hepatic glycogen synthesis during a hyperglycemic clamp was attributed to a decrease in hepatic glucokinase (GCK) expression and decreased synthesis of glycogen via the direct pathway. The decrease in GCK expression was associated with increased expression of activating transcription factor 3, a negative regulator of GCK transcription. These studies have demonstrated that PEPCK1 is integral to coordinating cellular metabolism in the liver and adipose tissue, although it does not directly effect hepatic glucose production or adipose glyceroneogenesis.

Pubmed ID: 30445425 RIS Download

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK079310
  • Agency: BLRD VA, United States
    Id: I01 BX000901
  • Agency: NIDDK NIH HHS, United States
    Id: R24 DK085638
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK090489
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK110147

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


JNK (FL) (antibody)

RRID:AB_632382

This polyclonal targets MAPK9

View all literature mentions

Phospho-SAPK/JNK (Thr183/Tyr185) Antibody (antibody)

RRID:AB_331659

This polyclonal targets Phospho-SAPK/JNK (Thr183/Tyr185)

View all literature mentions

GAPDH Antibody (FL-335) (antibody)

RRID:AB_10167668

This polyclonal targets GAPDH

View all literature mentions

Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb (antibody)

RRID:AB_2315049

This monoclonal targets Phospho-Akt (Ser473)

View all literature mentions

Akt Antibody (antibody)

RRID:AB_329827

This polyclonal targets Akt

View all literature mentions

G6Pase-alpha (H-60) (antibody)

RRID:AB_2107514

This polyclonal targets G6PC

View all literature mentions

caspase-1 p10 (M-20) (antibody)

RRID:AB_2068895

This polyclonal targets caspase-1 p10

View all literature mentions

PCK2 Antibody (antibody)

RRID:AB_10836185

This polyclonal targets PCK2

View all literature mentions